National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report

J Clin Lipidol. Mar-Apr 2015;9(2):129-69. doi: 10.1016/j.jacl.2015.02.003. Epub 2015 Apr 7.

Abstract

The leadership of the National Lipid Association convened an Expert Panel to develop a consensus set of recommendations for patient-centered management of dyslipidemia in clinical medicine. An Executive Summary of those recommendations was previously published. This document provides support for the recommendations outlined in the Executive Summary. The major conclusions include (1) an elevated level of cholesterol carried by circulating apolipoprotein B-containing lipoproteins (non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol [LDL-C], termed atherogenic cholesterol) is a root cause of atherosclerosis, the key underlying process contributing to most clinical atherosclerotic cardiovascular disease (ASCVD) events; (2) reducing elevated levels of atherogenic cholesterol will lower ASCVD risk in proportion to the extent that atherogenic cholesterol is reduced. This benefit is presumed to result from atherogenic cholesterol lowering through multiple modalities, including lifestyle and drug therapies; (3) the intensity of risk-reduction therapy should generally be adjusted to the patient's absolute risk for an ASCVD event; (4) atherosclerosis is a process that often begins early in life and progresses for decades before resulting a clinical ASCVD event. Therefore, both intermediate-term and long-term or lifetime risk should be considered when assessing the potential benefits and hazards of risk-reduction therapies; (5) for patients in whom lipid-lowering drug therapy is indicated, statin treatment is the primary modality for reducing ASCVD risk; (6) nonlipid ASCVD risk factors should also be managed appropriately, particularly high blood pressure, cigarette smoking, and diabetes mellitus; and (7) the measurement and monitoring of atherogenic cholesterol levels remain an important part of a comprehensive ASCVD prevention strategy.

Keywords: Atherogenic cholesterol; Atherosclerotic cardiovascular disease; Clinical recommendations; Coronary heart disease; Dyslipidemia; Lipoproteins; Low-density lipoprotein cholesterol.

MeSH terms

  • Apolipoproteins B / blood
  • Atherosclerosis / blood
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / pathology
  • Cardiovascular Diseases / blood
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / pathology
  • Cholesterol, LDL / blood
  • Disease Management
  • Dyslipidemias / blood
  • Dyslipidemias / drug therapy*
  • Dyslipidemias / pathology
  • Government Agencies
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Risk Factors

Substances

  • Apolipoproteins B
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors